Search

Your search keyword '"Michieli M."' showing total 37 results
Start Over Author "Michieli M." Search Limiters Peer Reviewed
37 results on '"Michieli M."'

1. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Author

González-Barca, E., Boumendil, A., Blaise, D., Trněný, M., Masszi, T., Finel, H., Michieli, M. G., Bittenbring, J. T., Gritti, G., Snowden, J. A., Bishton, M., Bruno, B., de Villambrosia, S. González, Janikova, A., Leleu, X., Anagnostopoulos, A., Poiré, X., Crysandt, M., Özkurt, Z. N., Vandenberghe, E., Itälä-Remes, M., Cahn, J. Y., Jantunen, E., Schroyens, W., Maertens, J., Esquirol, A., Dreger, P., Montoto, S., and Sureda, A.

Published
2020
Full Text
View/download PDF

3. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party

Author

Necchi, A, Miceli, R, Bregni, M, Bokemeyer, C, Berger, L A, Oechsle, K, Schumacher, K, Kanfer, E, Bourhis, J H, Massard, C, Laszlo, D, Montoro, J, Flechon, A, Arpaci, F, Secondino, S, Wuchter, P, Dreger, P, Crysandt, M, Worel, N, Kruger, W, Ringhoffer, M, Unal, A, Nagler, A, Campos, A, Wahlin, A, Michieli, M, Sucak, G, Donnini, I, Schots, R, Ifrah, N, Badoglio, M, Martino, M, Raggi, D, Giannatempo, P, Rosti, G, Pedrazzoli, P, and Lanza, F

Published
2016
Full Text
View/download PDF

18. P07 BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD) IN REAL‐LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL.

Author

Larocca, A., D'Agostino, M., Giuliani, N., Antonioli, E., Zambello, R., Ronconi, S., Vincelli, I. D., Ciceri, F., Falcone, A. P., Michieli, M., Cattel, F., Capra, A., Grasso, M., Cafro, A. M., Bonello, F., Floris, R., Offidani, M., Sciorsi, E., Pietrantuono, G., and Curci, P.

Published
2023
Full Text
View/download PDF

19. P957: CARFILZOMIB, LENALIDOMIDE, DEXAMETHASONE FOLLOWED BY A SECOND AUTO‐HCT IS AN EFFECTIVE STRATEGY IN FIRST RELAPSE MULTIPLE MYELOMA: A STUDY OF THE CHRONIC MALIGNANCIES WORKING PARTY OF EBMT.

Author

Tilmont, R., Yakoub‐Agha, I., Eikema, D.‐J., Zinger, N., Haenel, M., Schaap, N., Herrera Arroyo, C., Schuermans, C., Bethge, W., Engelhardt, M., Kuball, J., Michieli, M., Schub, N., Wilson, K. M. O., Bourhis, J. H., Mateos, M. V., Robin, N., Jost, E., Kröger, N., and Moraleda, J. M.

Published
2022
Full Text
View/download PDF

20. S300: HEALTH‐RELATED QUALITY OF LIFE IN TRANSPLANT‐INELIGIBLE REAL‐LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD)

Author

D'Agostino, M., Bringhen, S., Ria, R., Ciceri, F., Falcone, A. P., Michieli, M., Grasso, M., Pane, F., Quaresima, M., Cattel, F., Mirabile, M., Fioritoni, F., Petrucci, M. T., Cotugno, V., Capra, A., Pezzatti, S., Mosca Siez, M. L., Cantonetti, M., Margiotta Casaluci, G., and Bertazzoni, P.

Published
2022
Full Text
View/download PDF

21. S221: BORTEZOMIB TO R‐DHAP COMPARED TO R‐DHAP IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA ELIGIBLE TO STEM CELL TRANPLANTATION: FINAL RESULTS OF PHASE II RANDOMIZED FIL‐VERAL12.

Author

Chiappella, A., Balzarotti, M., Botto, B, Castiglione, A., Cavallo, F., Usai, S. V., Zanni, M., Califano, C., Re, F., Ghiggi, C., Olivieri, A., Corradini, P., Liberati, A. M., Volpetti, S., Michieli, M. G., Tucci, A, Gaidano, G., Tani, M., Ciambelli, F., and Musuraca, G.

Published
2022
Full Text
View/download PDF

22. Long term cryopreservation in 5% DMSO maintains unchanged CD34+ cells viability and allows satisfactory hematological engraftment after peripheral blood stem cell transplantation.

Author

Abbruzzese, L., Agostini, F., Durante, C., Toffola, R. T., Rupolo, M., Rossi, F. M., Lleshi, A., Zanolin, S., Michieli, M., and Mazzucato, M.

Subjects
STEM cell transplantation, CRYOPRESERVATION of organs, tissues, etc., DIMETHYL sulfoxide, BLOOD platelets, CD34 antigen, GRANULOCYTES, TREATMENT effectiveness, HEMOGLOBINS, HEMATOLOGY
Abstract

Peripheral blood stem cell cryopreservation is associated with cell damage and decreased viability. We evaluated the impact of up to 10 years of cryopreservation (5% DMSO) on viability of CD34+ cells utilizing graft samples of consecutive patients (2002-2012) with different malignancies who underwent stem cell collection and transplantation. Viability of CD34+ cells from oncohaematological patients measured after 5 weeks (97·2 ± 0·6%) or after 9-10 years of cryopreservation (95·9 ± 0·5%) was unaffected. Haemoglobin, granulocyte and platelet recovery after transplantation of long-term cryopreserved grafts occurred within 8-13 days. CD34+ stem cells can be safely stored up to 9-10 years, without affecting cell viability and clinical effectiveness. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

29. Oncologic drug shortages also in Italy.

Author

Tirelli, U., Berretta, M., Spina, M., Michieli, M., and Lazzarini, R.

Abstract

A letter to the editor is presented about the shortage of cancer drugs in the U.S. and Italy.

Published
2012

31. The German Hodgkin Study Group Stratification Scheme for Newly Diagnosed Hodgkin Lymphoma Is Useful for Predicting Outcome of Patients Receiving Radiation Therapy After Autologous Self Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma.

Author

Furlan, C., Michieli, M., Bortolus, R., Mascarin, M., Avanzo, M., Rupolo, M., Zanet, E., Filippi, A., Tirelli, U., and Trovo, M.

Subjects
*HODGKIN'S disease, *HEALTH outcome assessment, *CANCER radiotherapy, *CELL transplantation, *CANCER relapse, *DIAGNOSIS
Published
2014
Full Text
View/download PDF

36. The effect of a passive exoskeleton on trunk co-activation during liftings at different risk levels.

Author

Chini, G., Varrecchia, T., Silvetti, A., Tatarelli, A., Fiori, L., Draicchio, F., Serrao, M., Montante, B., Ciancia, R., Michieli, M., Rupolo, M., and Ranavolo, A.

Subjects
*INDUSTRY 4.0, *BIOMECHANICS, *PEOPLE with disabilities, *WIRELESS Internet, *ANALYSIS of variance
Abstract

The new Industry 4.0 scenarios offer opportunity for both the prevention of biomechanical overload risks and the implementation of extra return-to-work initiatives for people with disabilities. Wearable assistive devices (e.g., an industrial exoskeleton) can help to lower the risk of acquiring work-related musculoskeletal diseases (WMSDs) caused by manual material handling (MMH) tasks, among other things [1]. The most prevalent and expensive musculoskeletal diseases are WLBDs, which are primarily caused by manual lifting jobs [1]. This study aims to investigate the influence of TRUExo, a passive exoskeleton for the trunk composed of a textile and a mechanical component for energy restitution, on trunk coactivation in lifting activities at various risk levels (more details cannot currently be described because the device is under patent). Twelve healthy volunteers (age: 36.33±7.66 years; BMI: 22.34±2.21 kg/m2; 6 females and 6 males) completed the lifting tasks designed using the revised NIOSH lifting equation, [2], at progressively increasing lifting indexes (from 1 to 3). The tasks were performed with and without the TRUExo exoskeleton, and the activity of the erector spinae longissimus (RESL) and rectus abdominis superior (RAS) was recorded bilaterally using a 16-channel Wi-Fi transmission surface electromyograph (Mini Wave Infinity, Cometa, Milan, Italy) system at a sampling rate of 2000 Hz. Before beginning the lifting tasks, participants completed three repetitions of a specific exercise to record the isometric maximal voluntary contractions (iMVCs) for the muscles under investigation. Then, after sEMG processing and normalization respect to iMVC values, we computed the time-varying multi-muscle co-activation function (TMCf), [3]. Our findings reveal that the mean TMCf of all patients is lower with the passive exoskeleton than without it at each LI. The mean of the TMCf reduces significantly with LI when wearing the exoskeleton, according to two-way repeated-measures ANOVA and post-hoc analysis (Fig. 1B). The results reveal that the TMCf increases in relation to the risk levels both with and without the exoskeleton, but the TMCf is lower at each LI when the subject wears the exoskeleton (Fig. 1, B). These findings could lend credence to the notion that a passive exoskeleton worn during a working activity could alleviate biomechanical load and, as a result, lower the likelihood of WMSD occurrence. Furthermore, our findings highlight the TMCf's sensitivity to differentiate different risk levels even when wearing an exoskeleton, implying that it might be used as an operational tool to assess biomechanical risk in situations where traditional approaches (e.g., NIOSH's method) cannot be used. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results